FDA Orange Book · active-ingredient family
Clotrimazole
Clotrimazole: 18 brands, 14 generics; first approved Jun 17, 1983; generic available.
Generic available4 exclusivity periodsHas discontinued products
Generic status & protection
Generic available: 14 ANDA applications approved.
Earliest patent expiry Latest exclusivity ends
Brands (NDA)
18
Generics (ANDA)
14
Listed patents
1
Next patent expiry
May 26, 2042
in 16 yr
Brand (NDA) products
Originator applications
- CARWIN PHARM ASSOCNDA 2176282025
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% SOLUTION/DROPS OTIC Rx — - BAYER HEALTHCARE LLCNDA 0205741998
Approved strengths under this FDA application. Strength Dosage form Route Status TE 2% CREAM VAGINAL Discontinued — - BAYER HEALTHCARE LLCNDA 0205261996
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1%,200MG CREAM, TABLET TOPICAL, VAGINAL Discontinued — - BAYER HEALTHCARE LLCNDA 0205251996
Approved strengths under this FDA application. Strength Dosage form Route Status TE 200MG TABLET VAGINAL Discontinued — - BAYER HEALTHCARE LLCNDA 0202891993
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1%,100MG CREAM, TABLET TOPICAL, VAGINAL Discontinued — - BAYER HEALTHCARE LLCNDA 0180521990
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% CREAM VAGINAL Discontinued — - BAYER HEALTHCARE LLCNDA 0177171990
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MG TABLET VAGINAL Discontinued — - MYCELEXRLDBAYER HLTHCARENDA 0187131983
Approved strengths under this FDA application. Strength Dosage form Route Status TE 10MG TROCHE/LOZENGE ORAL Discontinued — - LOTRIMINRLDSCHERING PLOUGHNDA 017619—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% CREAM TOPICAL Discontinued — - LOTRIMINRLDSCHERING PLOUGHNDA 017613—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% SOLUTION TOPICAL Discontinued — - MYCELEXRLDBAYER HLTHCARENDA 018181—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% SOLUTION TOPICAL Discontinued — - SUN PHARMA CANADANDA 0211432000
Approved strengths under this FDA application. Strength Dosage form Route Status TE 2% CREAM VAGINAL OTC — - BAYER HEALTHCARE LLCNDA 0203891994
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1%,100MG CREAM, TABLET TOPICAL, VAGINAL Discontinued — - BAYER HEALTHCARE LLCNDA 0182301991
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% CREAM VAGINAL Discontinued — - BAYER HEALTHCARE LLCNDA 0181821991
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MG TABLET VAGINAL Discontinued — - BAYER PHARMSNDA 0190691985
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG TABLET VAGINAL Discontinued — - SCHERINGNDA 0188131984
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% LOTION TOPICAL Discontinued — - BAYER HEALTHCARE LLCNDA 018183—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% CREAM TOPICAL Discontinued —
Generic (ANDA) products (14)
Abbreviated applications
- CLOTRIMAZOLETHINQ PHARM-CRO PVTANDA 2156412024
Approved strengths under this FDA application. Strength Dosage form Route Status TE 10MG TROCHE/LOZENGE ORAL Rx AB - CLOTRIMAZOLESCIEGEN PHARMSANDA 2165692023
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% SOLUTION TOPICAL Rx AT - CLOTRIMAZOLETP ANDA HOLDINGSANDA 2122812019
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% SOLUTION TOPICAL Rx AT - CLOTRIMAZOLENOVITIUM PHARMAANDA 2098152019
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% SOLUTION TOPICAL Rx AT - CLOTRIMAZOLEGLENMARK PHARMSANDA 0902192010
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% CREAM TOPICAL Rx AB - CLOTRIMAZOLEFOUGERA PHARMSANDA 0783382008
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% CREAM TOPICAL Rx AB - CLOTRIMAZOLEPADAGIS USANDA 0767632005
Approved strengths under this FDA application. Strength Dosage form Route Status TE 10MG TROCHE/LOZENGE ORAL Rx AB - CLOTRIMAZOLERSHIKMAANDA 0763872004
Approved strengths under this FDA application. Strength Dosage form Route Status TE 10MG TROCHE/LOZENGE ORAL Rx AB - TEVA PHARMSANDA 0732491998
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MG TABLET VAGINAL Discontinued — - CLOTRIMAZOLERSSUN PHARMA CANADAANDA 0745801996
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% SOLUTION TOPICAL Rx AT - CLOTRIMAZOLESUN PHARMA CANADAANDA 0726411995
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% CREAM VAGINAL OTC — - CLOTRIMAZOLETEVAANDA 0733061995
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% SOLUTION TOPICAL Rx AT - CLOTRIMAZOLERSSUN PHARMA CANADAANDA 0726401993
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% CREAM TOPICAL Rx AB - CLOTRIMAZOLERSENCUBEANDA 0741651993
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% CREAM VAGINAL OTC —
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Marketing exclusivity
Hatch-Waxman
- NPNew product exclusivity (3 years)
in 2 yr 2 mo
- ODE-549Orphan-drug exclusivity (7 years)
in 6 yr 3 mo
- GAINQualified infectious disease product exclusivity (adds 5 years)
in 11 yr 3 mo
- GAINQualified infectious disease product exclusivity (adds 5 years)
in 7 yr 3 mo
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 12246006 | in 16 yr | ProductU-4276 |
Approval history
FDA approval span
First approval
43 yr 9 mo ago
Most recent approval
11 mo ago
Approvals span 1983–2025 across 32 FDA applications.
Brand (NDA) 1856%
Generic (ANDA) 1444%
Clotrimazole: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.

